List view / Grid view
18 August 2016 | By The Institute of Cancer Research, London
In a study of nearly 2000 patients, researchers found that women whose tumours had high F12 activity and low STC2 activity had a 32% chance of dying within 10 years, whereas those with low F12 activity and high STC2 activity had only a 10% chance of dying...
18 August 2016 | By The National Institute for Health and Care Excellence (NICE)
When initially reviewed, the committee concluded that the drug was too expensive compared to the current standard of care. Pfizer submitted further evidence, including a new patient access scheme that provided the drug at a lower price alongside revised analyses, which the committee then concluded could now be considered value…
17 August 2016 | By Evgen Pharma
The primary objectives of the STEM (SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer) trial are to use tumour imaging to evaluate safety and efficacy in patients starting to become resistant to mainstream hormone therapy...
16 August 2016 | By Janssen
Following succesful phase II trials, the FDA have granted a Breakthrough Therapy Designation for esketamine, an investigational antidepressant medication...
16 August 2016 | By ViiV Healthcare
ViiV Healthcare is undertaking two identical studies as part of a global phase III programme comparing a two-drug regimen of dolutegravir plus lamivudine, with a three-drug regimen of dolutegravir (Tivicay), plus the fixed-dose tablet tenofovir/emtricitabine (Truvada), to support regulatory filings as a treatment for HIV, for adults who have had…
16 August 2016 | By University of Florida
Scientists have found that using magnetic resonance imaging reveals areas where Parkinson’s disease causes progressive decline in brain activity, a biomarker discovery which will help to evaluate new experimental treatments to slow or stop the disease’s progression...
15 August 2016 | By National Institute for Health and Care Excellence (NICE)
A higher dose of ticagrelor is already recommended for 12 months after a heart attack. Now new draft guidance is recommending it is continued in these people at a lower dose for a further three years to reduce their risk of a further heart attack or stroke...
15 August 2016 | By Sanofi
Results of the study affirm the vaccine's consistent efficacy in reducing dengue in two-thirds of the study participants, aged 9 and older. It also documents the ability of the vaccine to prevent 8 out of 10 hospitalisations and up to 93% of severe dengue cases in this age group during…
12 August 2016 | By Niamh Louise Marriott, Digital Content Producer
Searching for answers through a series of biochemical tests, the scientists discovered that the patient had a cerebrospinal fluid deficiency in biopterin, a protein involved in the synthesis of several brain signalling chemicals called neurotransmitters. After receiving an analogue of biopterin to correct the deficiency, the patient's depression symptoms largely…
12 August 2016 | By Acacia Pharma
Acacia Pharma’s phase 3 trial, comprised of 568 patients, compared two doses of Baremsis (amisulpride injection, formerly APD421), a dopamine D2/D3 antagonist antiemetic, against placebo in patients with established nausea and/or vomiting after surgery (PONV), who had not previously received any prophylactic antiemetics...
11 August 2016 | By KalVista
This first clinical study will evaluate the key characteristics of safety, drug exposure and bioactivity (plasma kallikrein inhibition) achieved after oral dosing of KVD818. This clinical trial is being conducted in the UK with results of the study expected in spring 2017...
Yusen Logistics, a leading third-party logistics provider, is expanding its air freight forwarding network in Mexico with the addition of a branch in Guadalajara.
10 August 2016 | By Niamh Louise Marriott, Digital Content Producer
Bonesupport’s Fortify study will evaluate the safety and efficacy of Cerament G as part of surgical repair of open diaphyseal tibial fractures. The trial will enrol up to 230 patients at up to 30 centres globally, with the aim of having at least 50% of the study data coming from…
9 August 2016 | By AstraZeneca
The results showed that the trial did not meet its primary endpoint of progression-free survival (PFS), and selumetinib did not have a significant effect on overall survival (OS). The adverse event profiles for selumetinib and docetaxel were consistent with those seen previously...
9 August 2016 | By MSD
Following successful phase 3 clinical trials, in which MSD’s new Hepatitis C drug, Zepatier, performed well, achieving high virologic cure rates across the study, the European Commission has licensed the drug for sale in the European market, specifically for the treatment of chronic hepatitis C virus (HCV) in adults with…
